Short answer
Xeris Biopharma Holdings, Inc. (XERS) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Director Jeffrey Sherman retiring after serving since 2021; no reelection at 2026 Annual Meeting.
Xeris Biopharma Holdings, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Director Jeffrey Sherman retiring after serving since 2021; no reelection at 2026 Annual Meeting
- Board size reduced from eight to seven directors upon term expiration
- Sherman remains on Compensation and Nominating and Corporate Governance Committees until annual meeting
- Retirement unrelated to disagreements with company operations, policies, or practices
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xeris Biopharma Holdings, Inc. 8-K filings
Get the next XERS 8-K as it lands
Follow XERS for push alerts, or ask the research agent what this filing means.